PKC-zeta-dependent Sp1 Phosphorylation: Regulatory Insights using Novel Phospho-Specific Sp1 Antibodies and Peptide Decoys

PKC-zeta 依赖性 Sp1 磷酸化：使用新型磷酸化特异性 Sp1 抗体和肽诱饵获得监管见解

• 批准号: DP0663378
• 负责人: Prof Levon Khachigian
• 金额: $ 18.99万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0663378
• 关键词: PKC; zeta; dependent; Sp1; Phosphorylation

This project will demonstrate the value of novel phospho-specific Sp1 antibodies and phospho-Sp1 peptide decoys as new molecular tools to provide invaluable insights into the regulatory roles of phosphorylated Sp1 in the control of gene expression, an area poorly defined at the present time. These agents will be used to increase our fundamental understanding of Sp1 activity by identifying physiologic agonists of the PKC-zeta-phospho-Sp1 axis and FasL-dependent apoptosis, interactions of phospho-Sp1 with the authentic FasL promoter and its recruitment of collaborative factors. The commercial exploitation of phospho-specific Sp1 antibodies and phospho-Sp1 peptide decoys will generate economic returns to Australia.

该项目将展示新的磷酸化特异性Sp1抗体和磷酸化Sp1肽诱骗作为新的分子工具的价值，以提供对磷酸化Sp1在基因表达控制中的调节作用的宝贵见解，这一领域目前还没有明确的定义。这些药物将用于通过鉴定PKC-Zeta-磷酸-Sp1轴和依赖于FasL的细胞凋亡的生理学激动剂、磷酸化Sp1与真正的FasL启动子的相互作用以及它对协同因子的招募来加深我们对Sp1活性的基本了解。磷酸化Sp1抗体和磷酸化Sp1肽诱饵的商业开发将为澳大利亚带来经济回报。